BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

FDA Approved typed words on a vintage typewriter
BioCryst gets FDA approval of first oral prophylaxis for HAE

With the market for prophylaxis of hereditary angioedema dominated by injectable therapies, BioCryst Pharmaceuticals, Inc. believes it is poised to capture significant market share with the first US approval of an oral agent, kallikrein inhibitor Orladeyo (berotralstat) – and to make sure of that it is undercutting the price of the segment leader, Takeda Pharmaceutical Co. Ltd.’s Takhzyro.

BioCryst’s Orladeyo obtained US Food and Drug Administration approval on 3 December, with approval in Japan expected before the end...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip